arrow
M

Michał Mielnik

Medical University of Lublin
H指数:11
被引数:527

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Belantamab mafodotin 联合硼替佐米和地塞米松在复发或难治性多发性骨髓瘤患者中的应用(DREAMM-7):一项全球、随机、开放标签、III期试验的更新总生存期分析

2025-07-150
PRE
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2024-08-0114
PRE
Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pre-treatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor

预测多发性骨髓瘤的化疗毒性: 治疗前血清细胞因子interleukin-6,interleukin-8,单核细胞趋化蛋白-1和血管内皮生长因子水平的预后价值

2024-05-230
OAAI